crispr technology pharma heavyweight novartis signed separate deals gene editing start ups intellia therapeutics caribou biosciences plans use crispr engineering immune cells blood stem cells research tool drug discovery weeks novartis fellow drugmaker astrazeneca sealed deals wellcome trust sanger institute innovative genomics initiative broad whitehead institutes massachusetts thermo fisher scientific complementing company house crispr program technology identify validate new targets preclinical models range disease areas immunotherapy firm juno therapeutics shook hands gene editing start editas create anticancer immune cell therapies vertex pharmaceuticals crispr therapeutics start inked agreement valued $ 2.6 billion regeneron pharmaceuticals formed patent license agreement ers genomics holds